anti-Xa assay


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.

anti-Xa assay

A test that monitors blood clotting in patients taking anticoagulant drugs, such as low molecular weight heparin or unfractionated heparin. Heparins bind to antithrombin, which inhibits clotting factor Xa. The degree to which factor Xa is inhibited is measured by this assay.
See also: assay
Mentioned in ?
References in periodicals archive ?
Fully automated Anti-Xa assays permit routine labs to easily monitor UFH.
Advantages of the anti-Xa assay include achievement of therapeutic goal within 24 hours or less, fewer dosage adjustments and laboratory tests reducing the potential for titration errors, and saved nursing time (Fruge & Lee, 2015).
Rivaroxaban: anti-Xa assay utilising a specific rivaroxaban calibrator
Recommendations for monitoring patients on LMWH (South African Society of Thrombosis and Haemostasis 2004) (4) * The patient's platelet count should be checked on initiation of LMWH, after 5 days, and thereafter not less than once every 3 months, while on therapy * Anticoagulant activity is measured using an anti-Xa activity assay * Anti-Xa measurement is only indicated in pregnancy, renal failure or in excessively obese patients in whom large doses are required * The anti-Xa assay must be calibrated for each LMWH tested * The anti-Xa assay is available for enoxaparin and nadroparin at Johannnesburg Hospital Haematology Laboratory, tel (011) 488-3068 or (011) 489-8552 * 5 ml citrated blood taken 3 hours after a LMWH dose is required for the assay Target levels: Prophylaxis target: 0.
Currently, the chromogenic anti-Xa assay is the preferred assay for measuring plasma rivaroxaban concentrations in the clinical laboratory.
In addition, calibrators with Riva concentrations of 0, 15, 60, 100, and 150 [micro]g/L were sent to 18 Finnish laboratories for the local anti-Xa assay of Riva.
5) This article also includes a discussion of the preferred method of monitoring LMWH by chromogenic anti-Xa assay.